Sequentify is a technology company.
Sequentify has raised $7.0M across 1 funding round.
Sequentify has raised $7.0M in total across 1 funding round.
# High-Level Overview
Sequentify is a biotechnology company that develops library preparation solutions for Next-Generation Sequencing (NGS), addressing a critical bottleneck in genomic sample processing.[1][2] Founded in 2021 and based in Rehovot, Israel, the company has raised $7M in funding and focuses on making genomic testing faster, more affordable, and accessible at scale.[1][2]
The company's core mission is to eliminate barriers to widespread NGS adoption by simplifying and reducing the cost of sample preparation—the step that occurs before DNA sequencing hardware processes samples.[2] Sequentify serves the healthcare and personalized medicine sectors, offering targeted sequencing panels for oncology, screening applications, and infectious disease diagnostics.[1] By reducing both time and cost in the library preparation stage, the company aims to democratize genomic diagnostics, making it as routine and accessible as a blood test.[6]
# Origin Story
Sequentify was founded in 2021 in Rehovot, Israel, emerging at a moment when the genomic sequencing industry faced a critical challenge.[1] While sequencing hardware costs had declined dramatically due to platform improvements, the bottleneck had shifted upstream to the library preparation stage—the labor-intensive and expensive process of preparing DNA samples for sequencing.[2]
The company's founding addressed this specific pain point by developing innovative library-prep solutions that drastically reduce both cost and processing time.[1] This timing proved strategic: as sequencing became cheaper, laboratories worldwide needed solutions to handle sample preparation at scale without proportional cost increases. The company's early traction is evidenced by its ability to secure $7M in funding and establish partnerships with research institutions and clinical laboratories.[2]
# Core Differentiators
# Role in the Broader Tech Landscape
Sequentify operates within the genomic democratization trend, where advances in sequencing technology are shifting from hardware innovation to workflow optimization.[2] The company is riding several converging forces: declining sequencing costs have made population-wide genomic testing economically feasible, but sample preparation remains a bottleneck preventing widespread clinical adoption.
The timing is critical because healthcare systems and research institutions increasingly recognize genomic testing as essential for precision medicine, oncology diagnostics, and infectious disease management.[1] By solving the library preparation problem, Sequentify enables the decentralization of NGS—allowing smaller laboratories and clinics to perform high-throughput sequencing without massive capital investment or specialized expertise.[2]
The company's influence extends beyond healthcare into agri-tech, animal science, and research applications, positioning it at the intersection of multiple high-growth markets.[2] As NGS becomes routine rather than specialized, companies that simplify upstream workflows will become critical infrastructure in the genomic testing ecosystem.
# Quick Take & Future Outlook
Sequentify is well-positioned to capture significant market share as genomic testing transitions from specialized research to routine clinical diagnostics. The company's focus on reducing friction in sample preparation—rather than competing in the crowded sequencing hardware space—represents a smart market positioning strategy.
Looking ahead, Sequentify's growth will likely depend on expanding its panel offerings across disease areas, scaling manufacturing capacity, and building distribution partnerships globally.[2] As regulatory frameworks for genomic diagnostics mature and reimbursement improves, demand for simplified, cost-effective library preparation solutions will accelerate. The company's early focus on clinical applications and quality accreditation positions it to capture this opportunity as genomic testing becomes as routine as traditional laboratory diagnostics.
Sequentify has raised $7.0M in total across 1 funding round.
Sequentify's investors include Corazon Capital, Kamay Ventures, Maven Ventures, Montage Ventures, OurCrowd, Preetha Parthasarathy.
Sequentify has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Seed in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $7.0M Seed | Corazon Capital, Kamay Ventures, Maven Ventures, Montage Ventures, OurCrowd, Preetha Parthasarathy |